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HLA MATCHING AT DNA LEVEL AND ITS IMPACT ON THE OUTCOME OF
PEDIATRIC TRANSPLANTS FOR LEUKEMIA IN MULTI-RACIAL SINGAPORE
Tan, P.-L., Villegas, M.S., Chua, H.-C., Yeoh, A., Quah, T.-C. National
University Health System, Singapore, Singapore, Singapore
We retrospectively reviewed the outcome of hematopoietic stem
cell transplants (HSCT) in pediatric patients from a multi-racial
background with acute and chronic leukemia based on the degree
of HLA match at allelic/ DNA levels. We compared the rates of
transplant related mortality (TRM), graft versus host disease
(GVHD), relapse and overall survival (OS) in patients receiving re-
lated and unrelated donor HSCT with HLAmatch or mismatch do-
nors. Between January 1998 and October 2010, 56 HSCT were
performed in 52 patients whose median age was 110 (range, 12 –
226) months old. HLA match was defined as DNA match at 8 loci
(HLAA, B, C andDRB1*).Matching at DNA level became standard
from October 2004 and was available for 50 of the HSCT reviewed.
For the 6HSCTHLA typed prior to this time, related and unrelated
donor HSCT were assigned as match and mismatch, respectively.
HLA match grade of up to 4 alleles mismatches or a 1 antigen mis-
match was acceptable. Amongst the 56 HSCT, indications included
acute lymphoblastic leukemia (N 5 20), acute myeloid leukemia
(N 5 21), acute biphenotypic leukemia (N 5 4), chronic myeloid
leukemia (N 5 10) and juvenile myelomonocytic leukemia (N 5
1). Of all the HSCT, 20were related donor HSCT (11 bonemarrow,
8 peripheral blood) and 36 were unrelated donor HSCT (19 bone
marrow, 4 peripheral blood, 12 cord blood). At a median follow-
up of 1.44 (0.02 – 10.75) years, the results are shown in the table.Table 1. Results
Results
(N555)
MRD
(N517)
MMRD
(N53)
MUD
(N510)
(9 ASC + 1 CB)
MMUD (N525)
ASC
(N514)
CB
(N511)
TRM 6% (1/17) 0% 0% 0% 18% (2/11)
Acute
GVHD
grade
2 to 4
41% (7/17) 67% (2/3) 80% (8/10) 71% (10/14) 27% (3/11)
Chronic
GVHD
18% (3/17) 67% (2/3) 50% (5/10) 57% (8/14) 27% (3/11)
Relapse 24% (4/17) 0% 0% 14% (2/14) 36% (4/11)
Overall
Survival
76% (13/17) 67% (2/3) 100% (10/10) 71% (10/14) 82% (9/11)
*1 patient with missing data. MRD: matched related donor; MMRD:
mismatched related donor; MUD: matched unrelated donor; MMUD:
mismatched unrelated donor; ASC: adult stem cells (either bone mar-
row or peripheral blood stem cells); CB: cord bloodTwo-thirds of our patients lack suitably matched related donors. Of
all unrelated donor HSCT, 2/3 had HLA mismatch unrelated
HSCT: excluding CB recipients; the TRM was low; GVHD rates
were higher with correspondingly lower relapse rates compared to
patients who received HLA match related donor HSCT. Patients
who received HLA match unrelated donor typed at DNA level fare
the best.Table 1. Transplant Survival-Cord Blood
Survival >100 Days >1 Year >3 YEars
Related EFS 100% 100% 100%
Related OS 100% 100% 100%
Unrelated (UR) EFS 67% 60% 61%
UR OS 68% 66% 61%
UR Malignant EFS 70% 63% 57%
UR Malignant OS 72% 67% 57%
UR Non-malig. EFS 62% 55% 52%
UR Non-malig. OS 62% 63% 61%
UR Malig. EFS after 2002 80% 74% 74%
UR Malig. OS after 2002 83% 79% 74%283
DYSLIPIDEMIA FOLLOWING PEDIATRIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Marron, J.M.1, Kharbanda, S.1,2, Craveiro, L.2, Balise, R.R.3,
Agarwal, R.1,2 1Lucile Packard Children’s Hospital at Stanford Univer-
sity, Palo Alto, CA; 2Lucile Packard Children’s Hospital at Stanford Uni-
versity, Palo Alto, CA; 3Stanford University, Stanford, CA
Background: Children who receive solid organ transplants have
been shown to frequently develop dyslipidemias after transplant
due to the effect of immunosuppressive regimens on various lipid
metabolism pathways. Little data exists to date, however, regarding
the effect of hematopoietic stem cell transplantation (HSCT) onlipid profiles in the pediatric population, most of whom receive sim-
ilar immunosuppressive therapies to their solid organ counterparts.
Methods: Baseline total cholesterol and triglyceride concentrations
were collected just prior to transplant for 61 children who underwent
HSCT between 2000 and 2009 at Lucile Packard Children’sHospital.
Comprehensive lipidpanelswere thencollected at eachpatient’s annual
post-transplant follow-up visit. Age at the time of transplant ranged
from ten months to twenty years, and follow-up time ranged between
one andnineyears post-transplant. 59%ofpatientsweremale.Twopa-
tients required a second transplant. 74% of patients underwent alloge-
neic transplants; the remainder received autologous transplants. 55%of
allogeneic recipients developed acute graft-versus-host disease
(GVHD), and 36%developed chronicGVHDduring their post-trans-
plant course. Patients who developed GVHD were treated with ste-
roids and a calcineurin inhibitor for an extended length of time.
Results:Mean pre-transplant total cholesterol concentrations were
136 mg/dL, below the 20th percentile for US children and adoles-
cents. By four years post-transplant, triglyceride concentrations in-
creased by 30% (to 130 mg/dL) and total cholesterol by 39% (to
189 mg/dL) from pre-transplant values. This total cholesterol con-
centration is above the 80th percentile for US children and adoles-
cents. Between year one and year four post-transplant, low-density
lipoprotein concentrations increased by 33% to 117 mg/dL, which
is at the 85th percentile for US children and adolescents.
Conclusion:Dyslipidemias affect a significant proportion of pediat-
ric HSCT recipients. This is likely due at least in part to immuno-
suppressive medications, particularly in those with GVHD
requiring prolonged immunosuppressive treatment. The number
of affected individuals increases with time since transplant, placing
transplanted patients at increased risk for early cardiovascular dis-
ease. Further studies are necessary to determine if intervention, ei-
ther pharmacologic or otherwise, is advisable for HSCT recipients
in order to mitigate this increased risk.284
CORD BLOOD TRANSPLANTATION: 16 YEAR PEDIATRIC EXPERIENCE AT
A SINGLE INSTITUTION
Brown, B., Kempert, P., Chon, A., Taylor-Smith, L., Reyes, D.R.,
Ikeda, A., Moore, T.B. David Geffen School of Medicine at UCLA, Los
Angeles, CA
Background:Cord blood is increasingly being used as an alternative
stem cell source for hematopoietic stem cell transplantation
(HSCT). We report the experience from a single institution and
the impact of Center experience, improving supportive care, and in-
creasing choice of cord units banked on outcome over time.
Methods: A retrospective chart review was performed reviewing all
pediatric hematopoietic stem cell transplants over a 16 year period.
Results:Over a 16 year period 435HSCT’s were performed. Eighty
of these were performed using cord blood as the stem cell source.
Four were from related donors (RD) and 76 were from unrelated do-
nors (URD). Twenty sevenwere transplanted for non-malignant dis-
eases (NMD) (26 URD; 1 RD) and 53 with malignant disease (MD)
(50 URD; 3 RD). Patients transplanted with related donors for ma-
lignant (3) and non-malignant (1) conditions had EFS and OS of
100% and 100% respectively. Incidence of acute GVHD grade II-
IV was 50% and Grade III-IV was 0 with no chronic GVHD. Se-
venty-six patients were transplanted with unrelated donors using
TBI and non-TBI containing regimens depending on disease. Im-
munosuppression for the majority (83%) consisted of CSA with
